Jan 9, 2009 | 1
Some consumer groups are bleating over the prospect of a new anti-clotting drug made from genetically modified goats.
An advisory committee to the Food and Drug Administration (FDA) is meeting today to discuss whether to recommend approval of ATryn, a med made from the milk of goats engineered to produce copious amounts of the blood-thinning protein antithrombin. This is the first time an FDA panel is considering a commercial food or drug product produced from a genetically altered animal.
(See a story from our September 2006 issue for more on ATryn.)
ATryn, manufactured by Massachusetts-based biotech GTC Biotherapeutics, is not being mulled as a sub for traditional blood thinners, but rather for use during surgery or childbirth for the one in 5,000 Americans with antithrombin deficiencies at increased risk of developing potentially fatal blood clots in their lungs or brains, the Associated Press says.
Deadline: Dec 11 2013
Reward: $52,000 USD
Platform technologies – tools, techniques, and instruments that enable entirely novel approaches for scientific investigation across a b
Deadline: Jan 11 2014
Reward: $20,000 USD
Conventional washing machines cause excessive damage and wrinkling to clothes primarily during the water removal step. With the introduc
Give a 1 year subscription as low as $14.99X